CNS Pharmaceuticals, Inc. Common Stock
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Open CNSP dashboard ↗Lexaria Bioscience Corp. Common Stock
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Open LEXX dashboard ↗